Bio-Techne Corp: stock overview

TECHNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$72.80

November 13, 2026Market cap $11.4B

DCF calculator

What Ploutos Investor adds for Bio-Techne

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Bio-Techne had revenue of $1.2B over the last 12 months and net income of $172M, a net margin of 14.0%. Revenue grew by 5.5% a year on average over the last 5 years. At $72.80 the shares trade at a P/E of 66.5, against a median of 56.6 over the last 4 fiscal years. It has net debt of $50M. It pays a dividend yielding 0.44%.

From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$11.4B
157M shares
P/E
66.5
Today66.5
Median56.6
Revenue, 12 months
$1.2B
+5.5% a year over 5 years
Net margin
14.0%
FY2025: 6.0%, above 68% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

+2.4% a year over 2 years

  • FY2026Jun 30, 202610-K
    Revenue$1.2B
  • FY2025Jun 30, 202510-K
    Revenue$1.2B
  • FY2024Jun 30, 202410-K
    Revenue$1.2B

Fiscal years in figures

TECH's revenue, profit, cash flow and dividend with each year-end price, from FY2010 to FY2023, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $11.1B
$11.4B
Enterprise value 
$11.5B
P/E 
66.5
EV / EBIT 
47.7
EV / Revenue 
9.4
P/B 3-year median: 5.3
5.3
FCF yield 3-year median: 2.4%
2.7%
Earnings yield 3-year median: 1.5%
1.5%

Profitability

Gross margin 
65.8%
Operating margin 
19.6%
Net margin 3-year median: 14.5%
14.0%
ROIC 
7.7%
ROIC, 5-year average 
8.2%
ROE 
8.3%

Growth

Revenue, yearly change 
-0.4%
EPS, yearly change 
+152.2%
FCF, yearly change 
+2.6%
Revenue, average a year 
+5.5%
EPS, average a year 
+5.9%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$350M
Total debt 
$486M
Of which operating leases 
$86M
Net debt 
$50M
Net debt / EBITDA 
0.2x
Interest cover 
27.2x
Current ratio 
2.28

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 0.5%
0.44%
Buybacks 
0.36%
Total returned 
0.80%
Shares, yearly change 
+1.0%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

64.8%

Above 76% of the 141 companies in its industry, and 82% of all.

Operating margin

8.4%

Above 68% of the 285 companies in its industry, and 60% of all.

Net margin

6.0%

Above 68% of the 302 companies in its industry, and 55% of all.

ROE

3.7%

Above 60% of the 267 companies in its industry, and 39% of all.

ROA

2.9%

Above 64% of the 313 companies in its industry, and 60% of all.

Revenue growth

5.2%

Above 49% of the 292 companies in its industry, and 46% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
BIO-TECHNE Corp
CIK
842023
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
June 30
Latest annual report
June 30, 2026
Reporting currency
USD
Shares
157M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Bio-Techne's filings show?

These are Bio-Techne's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about TECH

Didn't find what you were looking for?

Ask us
What is TECH's market cap?

Bio-Techne Corp's market cap is $11.4B, at a price of $72.80 on November 13, 2026 and 157M shares.

What is TECH's P/E?

TECH's P/E is 66.5, on earnings per share of $1.09 over the last 12 months. The median over the last 4 fiscal years was 56.6.

How much revenue does TECH have?

Bio-Techne had revenue of $1.2B over the last 12 months. Over the last 5 years it changed by +5.5% a year on average.

Does TECH pay a dividend?

Yes. Bio-Techne paid $0.32 per share over the last 12 months, a yield of 0.44% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Bio-Techne Corp's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.